Arcturus Therapeutics Holdings Inc. (ARCT): Results of Operations and Financial Condition
Arcturus Therapeutics Holdings Inc. (ARCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026 ARCT-810 (OTC Deficiency) Phase 2 study enrollment and dosing completed; d
How this was made
The 30-second read
Why it matters
Key trading inputs are (1) time-stamped pipeline milestones for ARCT-032 and ARCT-810, and (2) the CSL Seqirus termination and settlement that returns global rights to KOSTAIVE and provides $12M cash plus ~$16M released liabilities/R&D credits, improving financial flexibility.
Market read
Investors get a clearer near-to-mid-term roadmap (Q3 2026 ARCT-810 data/regulatory plan; Q4 2026 ARCT-032 Phase 3 decision) and improved balance-sheet support from the CSL Seqirus settlement, but the release lacks new efficacy readouts.
What to watch
Thermo Fisher’s role is manufacturing and services, but the article does not quantify cost, timeline, or regulatory risk; also, revenue declines are tied to the collaboration wind-down, which may pressure near-term financial optics.
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
ARCT-032 enrollment remained on schedule and ARCT-810 completed enrollment and dosing, while revenue declined to $3.0 million from $28.3 million and net loss widened to $23.8 million from $9.2 million. The CSL Seqirus settlement adds a $12 million cash payment and approximately $16 million of released liabilities and R&D credits, alongside cash runway through year end 2028.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| RevenueGAAP | $3.0 million | – | – |
| Research and development expensesGAAP | $17.5 million | – | – |
| General and administrative expensesGAAP | $11.0 million | – | – |
| Net lossGAAP | $23.8 million | – | – |
| Net loss per shareGAAP | $0.84 | – | – |
| Six-month revenueGAAP | $5.0 million | – | – |
| Six-month research and development expensesGAAP | $39.0 million | – | – |
| Six-month general and administrative expensesGAAP | $20.5 million | – | – |
| Six-month net lossGAAP | $50.7 million | – | – |
| Six-month net loss per shareGAAP | $1.79 | – | – |
Q3 2026, Q4 2026 and year end 2028 outlook
- NoteData and the regulatory plan for ARCT-810 is expected to be communicated later this quarter.
- NoteThe decision to advance ARCT-032 into Phase 3 is expected in Q4 2026.
- Notecash runway of over two and a half years through year end 2028
What drove it
- Revenue decreases were primarily attributable to lower revenue recognized under the CSL Seqirus collaboration as the Company progressed toward termination of the agreement and regaining rights to KOSTAIVE® and its broader infectious disease vaccine portfolio.
- Research and development expense decreases were primarily driven by lower research and development spending, including reduced salaries, wages, benefits and facilities costs.
- ARCT-032 enrollment is advancing as expected, with active screening and enrollment in the U.S., Israel, and Turkey.
- ARCT-810 completed enrollment of the ongoing Phase 2 study, and all enrolled subjects completed study drug dosing.
- The Thermo Fisher Scientific collaboration will provide Phase 3 manufacturing, clinical research, and related services for ARCT-032.
Concerns
- Revenue was lower due to reduced revenue recognized under the CSL Seqirus collaboration.
- Net loss was higher than the comparable period last year.
- The decision to advance ARCT-032 into Phase 3 depends on Phase 2 progress and is expected in Q4 2026.
- ARCT-810 supplementary data evaluation and regulatory discussions remain pending.
- Future value realization for KOSTAIVE® and the broader infectious disease vaccine portfolio depends on development, commercialization, and partnering opportunities.
What to watch
- ARCT-810 data and the regulatory plan expected later this quarter.
- The expected Q4 2026 decision on advancing ARCT-032 into Phase 3.
- ARCT-032 Phase 2 enrollment progress and evidence of early clinical benefit, including ppFEV1, lung clearance index, quality-of-life measures, and HRCT imaging.
- The Company’s evaluation of development, commercialization, and partnering opportunities for KOSTAIVE® and the infectious disease vaccine portfolio.
- Cash runway through year end 2028 and clinical-development spending.
Balance sheet and cash flow
- Cash and cash equivalents were $191.5 million as of June 30, 2026.
- Cash and cash equivalents were $230.9 million on December 31, 2025.
- Cash and cash equivalents decreased by $39.4 million.
- CSL Seqirus will make a one-time cash payment of $12 million to Arcturus.
- Arcturus will be released from liabilities associated with an R&D credit with an aggregate value of approximately $16 million.
Analysis
Arcturus reported a quarter marked by clinical execution and sharply lower collaboration revenue. Revenue was $3.0 million, compared with $28.3 million in the comparable period last year, as revenue recognized under the CSL Seqirus collaboration declined while the parties moved toward termination of their agreement. The Company reported a net loss of $23.8 million, compared with a net loss of $9.2 million in the comparable period last year, and net loss per share was $0.84 compared with $0.34.
Operating spending was lower in research and development but general and administrative expense was modestly higher. Research and development expenses were $17.5 million, compared with $29.6 million, primarily reflecting lower research and development spending and reduced salaries, wages, benefits and facilities costs. General and administrative expenses were $11.0 million, compared with $10.3 million, with legal fees contributing to the increase partly offset by reduced salaries, wages, benefits and facilities costs. The reported expense pattern reflects prioritization of the ARCT-032 cystic fibrosis and ARCT-810 OTC deficiency programs.
Pipeline milestones are the central operating catalysts. ARCT-032 remains in an open-label Phase 2 study, with active screening and enrollment in the U.S., Israel, and Turkey, and the Company expects a decision on advancing into Phase 3 in Q4 2026. ARCT-810 has completed Phase 2 enrollment and dosing for all enrolled subjects; the Company expects to communicate data and a regulatory plan later this quarter. Thermo Fisher will provide Phase 3 manufacturing, clinical research, and related services for ARCT-032 if Phase 2 produces positive results.
The CSL Seqirus termination and settlement agreement changes the portfolio and financial backdrop. Arcturus regained global rights to KOSTAIVE® and the broader infectious disease vaccine portfolio, subject to existing arrangements with Meiji Seika Pharma for the 2026-2027 season in Japan. CSL Seqirus will make a one-time cash payment of $12 million, and Arcturus will be released from liabilities associated with an R&D credit with an aggregate value of approximately $16 million. The Company ended June 30, 2026 with cash and cash equivalents of $191.5 million, down from $230.9 million on December 31, 2025, and stated cash runway of over two and a half years through year end 2028.
The key tension is that collaboration revenue has fallen materially while the Company evaluates how to maximize the value of the returned vaccine assets and prepares for potential late-stage investment in ARCT-032. Investors will focus on ARCT-810 data and regulatory planning later this quarter, the Q4 2026 ARCT-032 Phase 3 decision, and the Company’s ability to sustain disciplined capital allocation while pursuing rare-disease milestones.
Management, verbatim
We are encouraged by the continued progress of our ARCT-032 Phase 2 cystic fibrosis study, with active screening and ongoing enrollment across sites in the United States, Israel, and Turkey. With dosing completed of all subjects in our ARCT-810 Phase 2 OTC deficiency study, we look forward to sharing the data and regulatory plan later this quarter.
Joseph Payne, President & CEO of Arcturus
The CSL Seqirus termination and settlement agreement strengthens our financial position, and the Thermo Fisher collaboration supports execution of late-stage development for our CF program. We continue to maintain a strong balance sheet and cash runway of over two and a half years through year end 2028, allowing our company to reach important clinical and regulatory milestones for its rare disease pipeline.
Dennis Mulroy, Chief Financial Officer of Arcturus
Not in the filing
stated, not guessed- Gross profit and gross margin
- Operating income or loss
- Non-GAAP financial measures
- Prior-quarter comparisons for reported financial metrics
- Reported percentage year-over-year changes for revenue, expenses, net loss, and net loss per share
- Cash flow from operations
- Free cash flow
- Debt
- Share repurchases
- Dividends
- Financial revenue guidance
- Gross-margin guidance
- Operating-expense guidance
- Tax-rate guidance
- Reportable segment revenue
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 financial results and pipeline/corporate updates for Arcturus Therapeutics.
Ticker impact
Arcturus reported Q2 2026 results and said ARCT-032 Phase 2 enrollment is on schedule, with Phase 3 decision expected in Q4 2026.
Moderately positive bias into the next quarter as investors price in Phase 3 go/no-go timing and improved funding visibility.
The filing adds concrete, time-bound program milestones (Phase 3 expected Q4 2026, ARCT-810 data/regulatory plan expected Q3 2026) and a $12M cash inflow plus ~$16M released liabilities/credits from the CSL Seqirus settlement, which can reduce financing overhang.
Market effects
Reinforces investor focus on mRNA rare-disease programs with clear Phase 2-to-Phase 3 transition timelines and manufacturing/partner support.
Limited direct regional read-through; clinical enrollment spans U.S., Israel, and Turkey but the disclosure is company-specific.
Global rights return for KOSTAIVE and infectious disease vaccines may affect competitive positioning in multiple geographies, though details are constrained by existing Japan season arrangements.
Counterpoint
The filing highlights progress but does not provide new clinical efficacy results; the Phase 3 decision is still conditional on Phase 2 outcomes.
Key entities
- issuerArcturus Therapeutics Holdings Inc.
Nasdaq-listed mRNA medicines company; disclosed Q2 2026 financials, ARCT-032 and ARCT-810 progress, and the CSL Seqirus settlement.
- collaboration_partnerThermo Fisher Scientific
Collaborator for ARCT-032 Phase 3 manufacturing and clinical research services under a stated agreement.
- collaboration_partnerCSL Seqirus
Terminated sa-mRNA collaboration; to pay $12M cash and release ~$16M in liabilities/credits to Arcturus.
- partnerMeiji Seika Pharma
Has existing arrangements for the 2026-2027 Japan season referenced in the KOSTAIVE rights return.
